bluuebunny/crossref_metadata_2025_split huggingface dataset:
Interrelationship of prolactin and its receptor in carcinoma of colon and rectum: A preliminary report
Authors: Bhatavdekar Jyotsna , Patel Devendra , Ghosh Nandita , Vora Hemangini , Shah Neelam , Karelia Nilkamal , Balar Damodar , Chikhlikar Priya , Dave Ruchita 
Published: February 2007

AbstractThe prolactin receptors (PRLR) were correlated with circulating prolactin arious clinicopathologic parameters to investigate its prognostic value in patients with colorectal cancer. The prolactin (by radioimmunoassay) and its receptors (by radioligand method) were estimated in a total of 71 male patients with colorectal cancer enrolled at the Gujarat Cancer and Research Institute, Ahmedabad. The patients were followed for a period of 3 years. We have observed that 51% colorectal tumors were PRLR+. Significant correlation was not observed between presence/absence of PRLR and clinicopathologic variables. Dukes' D patients were lost to follow‐up after 2–3 months; therefore, the results of prognostic significance were analysed only in patients with Dukes' A, B, and C (N = 64). Statistically significant difference in overall survival was not observed when the patients were subgrouped according to the presence/absence of PRLR and according to the cutoff level (i.e., 2%). PRLR+ hyperprolactinemic (Prolactin > 20.0 ng/ml plasma) patients had better overall survival than that of patients with PRLR− hyperprolactinemia, although the difference was statistically nonsignificant. However, PRLR− hyperprolactinemia patients had a more unfavourable prognosis than that of their counterparts. A similar trend was observed in patients with Dukes' B and C disease.Our preliminary study suggests an unequivocal finding, that PRLR−with concomitant hyperprolactinemia probably characterises a subgroup of patients with aggressive colorectal cancer. © Wiley‐Liss, Inc.
Role of intraoperative assessment of lymph node metastasis and serosal invasion in patients with gastric cancer
Authors: Korenaga Daisuke , Okuyama Toshiro , Orita Hiroyuki , Anai Hideaki , Baba Hideo , Maehara Yoshihiko , Sugimachi Keizo 
Published: February 2007

AbstractThe clinical diagnoses of nodal status (N) and tumor invasion (T) were performed intraoperatively during 1499 consecutive operations for gastric carcinoma and compared with subsequent pathologic diagnoses. An accurate macroscopic diagnosis of N stage was difficult; overall accuracy was only 56.6%. Intraoperative assessment of T stage (particularly of serosal invasion) was correct for 93.2% of early stages of the disease with invasion confined to the mucosa or submucosa (pT1) when the pathologist assessed the T stage in the resected specimen, for 95.6% of advanced tumors invading the serosa (pT3), but for tumors of an intermediate stage with invasion involving the muscularis propria or the subserosa (pT2) in only 41.9% of cases. Macroscopic overestimation occurred in 58.1% of cases with pT2 tumors, which were characterized by carcinomas in the upper third of the stomach, tumors larger than 5 cm, carcinomas of the ulcerating type, differentiated adenocarcinomas, tumors invading the subserosa, and those accompanied by lymph node metastasis or liver metastasis. The overestimated group had a significantly poorer prognosis than the correctly assessed cases (P < 0.05). Since multivariate logistic regression analysis showed that the significant risk factor related to the inaccurate intraoperative assessment of T stage was tumor size, the error in diagnosis may correlate with a greater degree of tumor spread. Surgeons should decide their therapeutic approach at the time of surgery on the basis of their intraoperative assessment of tumor spread. We recommend extensive surgery followed by adequate chemotherapy when serosal invasion is suspected at surgery. © Wiley‐Liss, Inc.
How does negative clinical evaluation of ovarian carcinoma after full course of chemotherapy correlate with second‐look laparotomy findings?
Authors: Zorlu Cahit Gürkan , Cobanoḡlu ömer , Caḡlar Turhan , Ergun Yusuf , Kuscu Esra , Alaybeyoḡlu Tuncay 
Published: February 2007

AbstractSurgical reexploration was performed in 46 patients with epithelial nonmucinous ovarian adenocarcinoma requiring adjuvant chemotherapy whose initial therapy consisted of optimum debulking and surgical staging. All patients were placed on CAP (cisplatinum, Adriamycin, cyclophosphamide) chemotherapy for at least six courses until proved to be clinically disease free (mainly CA‐125 below 35 U/ml and normal ultrasonography or computerized tomography). All women underwent second‐look laparotomy (SLL) after completion of adjuvant therapy. We classified SLL findings in five categories, namely, no evidence of disease, cytological evidence of disease, histological evidence of disease, macroscopic evidence of disease (<2 cm), and bulky tumor (>2 cm). SLL demonstrated 14 (30%) patients with disease. Of these, five cases had histological evidence of disease and nine had macroscopic disease; however, we found no patient with persistent disease larger than 1.5 cm. No patient in stage I demonstrated disease at SLL. All cases with macroscopic disease and three cases with histological disease were initially in stage III. We found that about one third of cases who were clinically free of disease had persistent disease at the completion of chemotherapy. Hence, we conclude that routine SLL is still of importance in the management of patients with epithelial ovarian adenocarcinoma except those with stage I disease. © Wiley‐Liss, Inc.
Surgery after radiochemotherapy for stage III lung cancer: Postoperative complications and late results
Authors: Tavecchio Luca , Ravasi Gianni , Bedini Amedeo V. , Gramaglia Alberto , Milani Franco 
Published: February 2007

AbstractFifty‐seven stage III lung cancer patients underwent radiochemotherapy and subsequent surgery. Forty radical (R−), six non‐radical, and eleven exploratory operations were performed. Pneumonia (five cases), pulmonary insufficiency (one case), bronchial fistula (one case) were the major non‐fatal complications. Four deaths due to adult respiratory distress syndrome (ARDS) or pulmonary embolism occurred. Sixty percent of the 10 patients who had no viable tumor at operation survived 3 years, as well as 41% of those who achieved a complete remission by resection and 11% of those with residual disease (R+) after operation. However, the 1‐ and 2‐year survival rates were similar. The main pattern of failure in R− and R+ patients was extra‐ and intra‐RT‐field progression, respectively. A slightly higher rate of postoperative complications, with respect to current practice, was observed. However, data lead to argument on the improvement of locoregional control and long‐term survival following radical surgery. © 1994 Wiley‐Liss, Inc.
Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: A prospective study
Authors: Casson Alan G. , McCuaig Sheryl , Craig Ian , Ayed Adel , Inculet Richard , Kerkvliet Nancy , O'Malley Frances 
Published: February 2007

AbstractThe aim of this prospective study was to determine whether use of a combination of biomarkers, p53 and nuclear DNA content, led to improved prognosis and Clinicopathologic correlation in human non‐small cell lung cancer. Nineteen patients undergoing curative resection of primary non‐small cell lung cancer were evaluated. Resected tumors were studied by polymerase chain reaction/single strand conformation polymorphism analysis (p53 gene mutations), flow cytometry (nuclear DNA content and cell cycle analysis), and immunohistochemically (p53 oncoprotein). Histologically normal lung was used as an internal control for each patient. Minimum postoperative follow‐up was 4 years. p53 gene mutations (5/19 tumors; 26%), tumor ploidy (5/19 diploid), patterns of immunoreactivity, or combination of biomarkers did not appear to correlate with clinicopathologic findings or clinical outcome. Two of three patients with associated second primary malignancies, had squamous cell diploid tumors with p53 gene mutations. We conclude that p53 gene mutations and tumor ploidy may represent different biologic markers for human nonsmall cell lung cancer. Although trends in improved predictive accuracy were not seen when both markers were incorporated into the tumor analysis, flow cytometry and molecular analysis of the p53 gene may identify patients at increased risk of the development of a second primary maligmancy. © 1994 Wiley‐Liss, Inc.
Wilms' tumor: Long‐term results from a single institution
Authors: Zaghloul Mohamed S. , Hussein M. Hany , El Koutbey Montasser 
Published: February 2007

AbstractOne hundred‐twelve children with pathological diagnosis of Wilms' tumor were treated during the period 1979–1989. They were postoperatively staged as follows: stage I, 25 patients; stage II, 27 patients; stage III, 48 patients; and stage IV, 9 patients. Three patients were preoperatively classified as stage V. The National Wilms' Tumor Study (NWTS) staging system was used. Except for Stage V patients, the treatment regimen consisted of nephrectomy followed by radiotherapy and/or chemotherapy according to stage of disease and pathology. Stage I, II, and III patients with favorable histology enjoyed 94 ± 6%, 86 ± 8%, and 71 ± 8% 10‐year actuarial survival, respectively. Stage IV patients and those in stages I, II, and III with unfavorable histology had a 10‐year actuarial survival of 36 ± 8%. Univariate analyses proved that NWTS stages affected the 10‐year actuarial disease‐free survival rates but not the overall survival rates. The histopathology significantly affected the disease‐free survival and the overall survival rates both in the whole group of patients and in each stage when considered separately. The same histopathology also affected the incidence of development of distant relapse but not the local recurrence rate.On the other hand, massive tumor rupture at surgery increased the incidence of local relapse but not of distant metastasis and did not affect the overall survival rates. The presence of residuum after surgery had nearly the same effect as tumor rupture on the local recurrence. It also did not increase significantly the distant relapse incidence, but it affected significantly the overall survival. Retroperitoneal lymph node involvement had a similar effect. It increased the incidence of local relapse and decreased the 10‐year overall survival rate but it had a borderline effect on development of distant metastasis (P = 0.06). The age at diagnosis had also a borderline effect on disease‐free survival but it had no effect, of statistical significance, on the overall survival. © 1994 Wiley‐Liss, Inc.
Short‐term intrahepatic FUdR infusion combined with bolus mitomycin C: Reduced risk for developing drug resistance
Authors: Arisawa Yoshito , Sutanto‐Ward Erika , Dalton Rory R. , Sigurdson Elin R. 
Published: February 2007

AbstractThis study evaluates tumor response, survival, and development of resistance to HAI chemotherapy, comparing a combination of bolus MMC and short duration FUdR to short duration FUdR alone or to long duration FUdR alone, using a rat hepatic metastases model. After intrasplenic injection of 107 K12/TRb colon cancer cells in BD‐IX rats on day 0, hepatic metastases were evaluated and HA catheters were placed on day 14. The response was determined on day 28. Chemosensitivity of the hepatic metastases after HAI treatments was determined using the MTT assay. Bolus MMC with short duration FUdR as well as long‐term FUdR alone provided better hepatic tumor response and survival than short‐term FUdR alone. However, bolus MMC with short duration FUdR decreased the acquired resistance to FUdR, compared to long‐term FUdR, without causing resistance to MMC. These results provide a rationale for using short duration of FUdR in combination with other drugs. © 1994 Wiley‐Liss, Inc.
Adult paratesticular sarcomas: A report of eight cases
Authors: Rao C. Rama , Srinivasulu M. , Naresh K. N. , Doval D. C. , Hazarika D. 
Published: February 2007

AbstractEight adult paratesticular sarcomas seen at a Regional Cancer Centre over a 7‐year period are described. There were three cases of rhabdomyosarcoma (RMS), three cases of leiomyosarcoma (LMS), and two cases of liposarcoma (LS). The RMS occurred in a younger age group (3rd decade) than the LMS and LS (6th and 7th decades). Most of our patients presented with advanced disease after orchiectomy at other hospitals, three with recurrent or residual disease and four with metastasis. The single patient with RMS who received intensive adjuvant therapy is free of disease at 84 months in spite of the advanced stage at presentation. All three patients with LMS had an unfavourable clinical course. Both the patients with LS had well differentiated (WD) tumours and presented with recurrences, one over several years, following initial local excisions.The necessity for early adequate surgical and adjuvant therapy and the need for a uniform treatment policy are discussed. © 1994 Wiley‐Liss, Inc.
Immunological profile changes following perioperative autologous vs. homologous blood transfusion in oncologic patients
Authors: Peller Shoshana , Sayfan Joel , Levy Yeheskel , Oland Jan , Yona Rivka , Kaufman Suzana , Orda Ruben 
Published: February 2007

AbstractTo determine the effect of perioperative blood transfusion on immunological parameters, T cells, T‐cell subsets, and concanavalin A‐induced suppression were measured in 25 patients with colorectal and breast cancer. During the operation, 15 patients received autologous blood and 10 patients had homologous transfusion. The immunological status was again determined after curative surgery. Before surgery, normal percentage of T lymphocytes, decreased ratios of helper/suppressor cells, and impaired con A‐induced suppression were found. Following the operation, the helper and suppressor cell percentages reversed to normal, whereas the con A‐induced suppression remained impaired. This change was significantly more pronounced in patients who received autologous blood transfusion than in the other group. Autotransfusion has an impact on immune parameters that might prove less detrimental to the clinical outcome in oncologic surgery than homologous transfusion. © 1994 Wiley‐Liss, Inc.
Local hyperthermia abrogates the anti‐immunotherapeutic effect of interleukin‐8
Authors: Geehan Douglas M. , Fabian Dagmar F. , Lefor Alan T. 
Published: February 2007

AbstractThe therapeutic efficacy of cellular immunotherapy depends not only on the anti‐tumor activity of the administered effector cells but also on their ability to gain access to the tumor by extravasation. Although interleukin‐8 (IL‐8) has been shown to prevent the vascular leak associated with IL‐2, it also abrogates the anti‐tumor effect of IL‐2. We undertook these studies to determine if LHT could abrogate the anti‐immunotherapeutic effect of IL‐8, since IL‐8 inhibits leukocyte adhesion. C57BL/6 mice were divided into four groups of six animals each after induction of MCA‐105 fibrosarcoma inoculated into the right bindlimb on day 0 and were treated begining on day 3 as follows: no therapy, IL‐2 alone (1.02 × 106 IU ip tid on days 3‐7), IL‐2 + IL‐8 (9.6 ng ip tid on days 3–7), and IL‐2 + IL‐8 + LHT (45C × 15 min on days 3, 5, and 7). Tumor growth was measured on days 10–21 and analyzed by Wilcoxon rank‐sum analysis. IL‐2 reduced tumor growth significantly (P < 0.05) compared to no therapy, and IL‐8 abrogated the anti‐tumor effect of IL‐2, resulting in tumor growth in animals receiving IL‐2 + IL‐8, similar to the no therapy group (P > 0.05). However, addition of LHT to IL‐2 + IL‐8 resulted in significantly (P < 0.05) less tumor growth than no therapy or IL‐2 + IL‐8. Activity of the mice was scored as an indicator of systemic toxicity. We found that IL‐8 was able to increase the activity (P = 0.07) of the mice when administered with IL‐2. These results suggest that IL‐8 may protect the tumorbearing animal from the systemic toxicity of IL‐2, while LHT abrogates the anti‐immunotherapeutic effect of IL‐8. © 1994 Wiley‐Liss, Inc.
High proliferative rates demonstrated by bromodeoxyuridine labeling index in breast carcinomas with p53 overexpression
Authors: Meyer John S. , He Weihua 
Published: February 2007

AbstractThe protein p53 is a product of a suppressor oncogene. Mutations occurring in 13–15% of breast carcinomas are associated with p53 stainability within nuclei and progression of the tumor. We determined the extent to which p53 abnormality was associated with proliferation by measuring p53 immunohistochemically with a polyclonal antibody and monoclonal PAb1801 in invasive carcinomas of known S‐phase fraction (SPF) assessed histologically by bromodeoxyuridine incorporation. Results with the two antibodies always agreed. One of 20 low, 2/18 midrange, and 9/17 high SPF carcinomas were positive for p53. P53 positivity was also related to other indicators of aggressiveness including size of primary tumor, nuclear and nucleolar size, and estrogen and progesterone receptor content, but relationships between p53 and vascular invasion and lymph node metastasis were not found. We conclude that nuclear p53 accumulation is more closely related to proliferation than to invasion and metastasis, and that it identifies some but not all breast carcinomas with high proliferative indices. © 1994 Wiley‐Liss, Inc.
Endoscopically guided placement of nasogastric tubes in patients with esophageal carcinoma with absolute dysphagia: Report of a 3‐year experience
Authors: Shukla Nootan Kumar , Goel Arun Kumar , Seenu Vuthaluru , Nanda Rajesh , Deo Suryanarayana V. , Kriplani Ajay Kumay 
Published: February 2007

AbstractEsophageal cancer often leads to total or near‐total dysphagia, necessitating placement of nasogastric tubes for nutritional support. In patients with failed blind intubation or even failed fluoroscopic‐guided tube placement, endoscopic guidance has a role to play. The catheter‐over‐guidewire technique is simple, safe, and easy to use. Over a period of 3 years, it was used in 28 patients who had esophageal cancer with absolute dysphagia. Successful placement of Levin tubes was achieved in 21 (75%) of these patients. Failure was more common in upper third lesions. The procedure was done on an outpatient basis, and no procedure‐related complications were recorded in this series. To summarize, endoscopically assisted nasogastric tube placement is a useful option in esophageal cancer when blind intubation has failed, and it should be considered in preference to fluoroscopic assistance if endoscopic facilities are available. © 1994 Wiley‐Liss, Inc.
Lipid peroxidation product in bile from patients with carcinoma of the gallbladder: A preliminary study
Authors: Shukla Vijay K. , Shukla Prabhat K. , Pandey Manoj , Rao Balaji R. , Roy Salil K. 
Published: February 2007

AbstractSamples of gall bladder bile from patients with and without carcinoma of the gallbladder were examined for lipid peroxidation (free radical oxidation) products. 4‐hydroxynonenal (HNE) was found in higher concentration in the bile of patients with carcinoma of the gall bladder. There was also a highly significant difference in the concentration of HNE among carcinoma of the gall bladder, cholelithiasis and control group of patients with miscellaneous abdominal disorders. This is the first study of lipid peroxidation in carcinoma of the gall bladder. © 1994 Wiley‐Liss, Inc.
Characterization of an established transplantable adenocarcinoma of the gallbladder in Syrian golden hamster
Authors: Inoue Keiji , Tomioka Tsutomu , Tajima Yoshitsugu , Fukahori Tomohiro , Eto Toshifumi , Tsunoda Tsukasa , Kanematsu Takashi 
Published: February 2007

AbstractA carcinoma of the gallbladder was transplantable in Syrian golden hamsters. The tumor was induced by subcutaneous injection of N‐nitrosobis (2‐oxopropyl) amine (BOP) following dissection of the common duct and preparation of a cholecysto‐duodenostomy. The histology revealed a poorly differentiated adenocarcinoma. The tumor was inoculated into the cavity of the gallbladder and subcutaneous tissue of the hamster and was transplantable (uptake rate was 100%). This tumor expressed blood grouprelated antigens, including A, H, and P‐glycoproteins. To our knowledge, this is the first report of carcinoma of the gallbladder transplantable in a laboratory animal. © 1994 Wiley‐Liss, Inc.
Flow cytometric analysis of variations in the DNA content of superficial and deep layers in colorectal cancer
Authors: Tomoda Hirotsugu , Kakeji Yoshihiro , Inoue Tetsuya 
Published: February 2007

AbstractWe investigated variations in the DNA content of multiple samples from both superficial and deep layers of tumors from 81 colorectal cancer cases. The findings were only diploid in 21 cases (25.9%) and only aneuploid in 49 cases (60.5%). On the whole, the DNA ploidy agreed in 70 cases (86.4%) between both layers. In the 49 cases with only aneuploid tumors in both layers, the DNA index (mean ± SD) was 1.58 ± 0.25 in the superficial layer and 1.59 ± 0.25 in the deep layer, with the values being almost identical. In contrast, a variation in the DNA ploidy of 11 cases (13.6%) was observed. These findings show that DNA ploidy remains stable during tumor progression from the superficial into the deep layers in most cases of colorectal cancer. However, the existence of heterogeneity in the DNA ploidy also shows that several specimens should be collected from both layers before making a determination of DNA ploidy. © 1994 Wiley‐Liss, Inc.
Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma
Authors: Shrayer David , Bogaars Hendrix , Gersten Douglas , Hearing Vincent , Maizel Abby , Wanebo Harold 
Published: February 2007

AbstractA model to study passive humoral immunotherapy of experimental melanoma was generated by subcutaneous injection of B16 F10 murine melanoma cells in the midtail of BALB/C nude (nu/nu) mice. Mice were challenged with melanoma cells pretreated: (1) with complete culture medium, (2) with 10% adjuvant control serum, (3) with 10% anti‐fECA (formalinized extracellular antigens) immune serum, or (4) with a monoclonal antibody (mAb H2‐3‐3) specific for the B700 melanoma‐associated antigen. All control mice challenged with melanoma cells pretreated either with culture medium or with medium containing adjuvant control serum (Groups I and II) died during the observation period of 84 days. At day 84, 60% of the mice challenged with melanoma cells pretreated with anti‐fECA immune serum (Group III) survived, as did 100% of the mice challenged with cells pretreated with mAb H2‐3‐3 (Group IV). Injection of melanoma cells pretreated with mAb H2‐3‐3 was associated with the greatest reduction of subsequent local tumor growth and the lowest number of metastatic lung tumors. The inhibitory effects of immune sera in vivo also correlated with in vitro effects of anti‐fECA immune serum and mAb H2‐3‐3, determined on B16 F10 melanoma target cells using assays for DNA synthesis and antibody dependant cellular cytotoxicity (ADCC). In sum, this nude mouse model for the study of passive humoral immunotherapy of experimental melanoma was utilized to demonstrate significant protective effects against B16 F10 melanoma cell challenge by treatment with anti‐fECA immune sera or a melanoma‐specific monoclonal antibody. © 1994 Wiley‐Liss, Inc.